Korean Society of Obesity "Caution of side effects such as pneumonia and pancreatitis of concern over abuse of gastric obesity"
Oct 23, 2024
With the obesity treatment "Wigobi" launched in Korea, the Korean Society of Obesity urged the health authorities to actively manage it to prevent misuse.
The Korean Society of Obesity said in a press release on the 23rd, `We welcome the launch of the semaglutide component 'Wigobi', a GLP-1 receptor agonist known as one of the most effective anti-obesity drugs, in Korea at a time when the obesity problem in Korea is becoming a serious social problem.' However, our society is deeply concerned about the situation in which incremental anti-obesity drugs can be misused and abused in our society while incremental anti-obesity drugs continue to be released in Korea.'
The association emphasized that `Incretin-based anti-obesity drugs are prescribed by doctors for the treatment of obese patients, and the subjects of this drug are clearly defined based on body mass index (BMI)."
Then "Incretin-based anti-obesity drugs can have a variety of side effects along with excellent weight loss effects. Common side effects include nausea, vomiting, constipation, diarrhea, and abdominal bloating. The risk of receiving cholecystectomy due to gallbladder disease may increase, and the risk of developing inhaled pneumonia may increase due to intestinal obstruction and delayed discharge of gastric contents. In addition, there is a possibility of pancreatitis, so monitoring of effects and side effects by medical staff is essential during use."
In addition, "When used for purposes other than indications for incretin-based anti-obesity drugs, such as beauty, not for the purpose of treating obesity diseases, they experience side effects rather than obtaining the therapeutic effect of drugs, which can increase the risk of hospitalization or death in medical institutions.".
In response, the society also asked government agencies to block illegal distribution and transactions and actively monitor side effects in order for incretin-based anti-obesity drugs to be used correctly and safely.
Meanwhile, Hugo Bee is an obesity treatment that acts on the glucagon-like peptide-1 (GLP-1) receptor, and it is a treatment that slows gastrointestinal movement and at the same time acts on the central nervous system to feel full and suppress appetite to lose weight. It started to be sold in Korea on the 15th.
In Korea, it can be prescribed to obese patients with a BMI of 30 or more or overweight patients with a BMI of 27 or less than 30 and accompanied by hypertension and dyslipidemia.
The Korean Society of Obesity said in a press release on the 23rd, `We welcome the launch of the semaglutide component 'Wigobi', a GLP-1 receptor agonist known as one of the most effective anti-obesity drugs, in Korea at a time when the obesity problem in Korea is becoming a serious social problem.' However, our society is deeply concerned about the situation in which incremental anti-obesity drugs can be misused and abused in our society while incremental anti-obesity drugs continue to be released in Korea.'
The association emphasized that `Incretin-based anti-obesity drugs are prescribed by doctors for the treatment of obese patients, and the subjects of this drug are clearly defined based on body mass index (BMI)."
Then "Incretin-based anti-obesity drugs can have a variety of side effects along with excellent weight loss effects. Common side effects include nausea, vomiting, constipation, diarrhea, and abdominal bloating. The risk of receiving cholecystectomy due to gallbladder disease may increase, and the risk of developing inhaled pneumonia may increase due to intestinal obstruction and delayed discharge of gastric contents. In addition, there is a possibility of pancreatitis, so monitoring of effects and side effects by medical staff is essential during use."
In addition, "When used for purposes other than indications for incretin-based anti-obesity drugs, such as beauty, not for the purpose of treating obesity diseases, they experience side effects rather than obtaining the therapeutic effect of drugs, which can increase the risk of hospitalization or death in medical institutions.".
In response, the society also asked government agencies to block illegal distribution and transactions and actively monitor side effects in order for incretin-based anti-obesity drugs to be used correctly and safely.
Meanwhile, Hugo Bee is an obesity treatment that acts on the glucagon-like peptide-1 (GLP-1) receptor, and it is a treatment that slows gastrointestinal movement and at the same time acts on the central nervous system to feel full and suppress appetite to lose weight. It started to be sold in Korea on the 15th.
In Korea, it can be prescribed to obese patients with a BMI of 30 or more or overweight patients with a BMI of 27 or less than 30 and accompanied by hypertension and dyslipidemia.
|
bellho@sportschosun.com
